Back to Companies
Aktis Oncology, Inc.
AKTSNasdaqCIK: 0002035832
Over the 29 most recent insider filings, Aktis Oncology, Inc. (AKTS) has seen activity from 17 distinct insiders — 6 buying and 3 selling. The activity is heavily weighted toward buying: $114.3M bought versus $3.0M sold, a net purchase of $111.3M. EcoR1 Capital, LLC (Director) is the most active by dollar volume, and the single largest transaction was $40.0M by EcoR1 Capital, LLC. All figures are drawn from official SEC Form 3, 4, and 5 disclosures and update as new filings arrive.
Total Volume
$118.8M
Purchases
$114.3M
Sales
$3.0M
Unique Insiders
17
Recent Insider Trades
29 loaded
| Jul 21 | AKTS Aktis Oncology, Inc. | Herrmann Ken | Insider | Sell | $119.3K |
| Jul 20 | AKTS Aktis Oncology, Inc. | Herrmann Ken | Insider | Sell | $77.3K |
| Jul 10 | AKTS Aktis Oncology, Inc. | Czibere Akos | Insider | Sell | $1.4M |
| Jul 10 | AKTS Aktis Oncology, Inc. | Ron-Bigger Shulamit | Insider | Sell | $1.4M |
| Apr 16 | AKTS Aktis Oncology, Inc. | Gormley Glenn | Insider | Award | $685.0K |
| Apr 16 | AKTS Aktis Oncology, Inc. | Gormley Glenn | Insider | Other | $0 |
| Jan 12 | AKTS Aktis Oncology, Inc. | Vida Ventures II, LLC | Insider | Buy | $15.0M |
| Jan 12 | AKTS Aktis Oncology, Inc. | EcoR1 Capital, LLC | Director | Buy | $40.0M |
| Jan 14 | AKTS Aktis Oncology, Inc. | MPM BIOVENTURES 2018, L.P. | Insider | Buy | $20.0M |
| Jan 15 | AKTS Aktis Oncology, Inc. | ELI LILLY & Co | Insider | Other | $0 |
| Jan 12 | AKTS Aktis Oncology, Inc. | Segal Lloyd Mitchell | Insider | Conversion | $0 |
| Jan 14 | AKTS Aktis Oncology, Inc. | GADICKE ANSBERT | Insider | Buy | $20.0M |
| Jan 12 | AKTS Aktis Oncology, Inc. | Kim Helen Susan | Insider | Buy | $15.0M |
| Jan 14 | AKTS Aktis Oncology, Inc. | Foley Todd | Insider | Buy | $4.2M |
| Jan 8 | AKTS Aktis Oncology, Inc. | EcoR1 Capital, LLC | Director, 10% Owner | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | Kuvalanka Kyle D. | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | Segal Lloyd Mitchell | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | MPM BIOVENTURES 2018, L.P. | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | Thistle Mary | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | Sherman Michael A. | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | Vida Ventures II, LLC | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | Herrmann Ken | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | Kim Helen Susan | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | Foley Todd | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | Feldman Paul L | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | GADICKE ANSBERT | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | Ron-Bigger Shulamit | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | RODEN MATTHEW | Insider | Other | $0 |
| Jan 8 | AKTS Aktis Oncology, Inc. | Czibere Akos | Insider | Other | $0 |
29 filings